Skip to main content
HR 3065 104th Congress House Health Drug utilization Drugs Environmental Protection Medical tests Pharmaceutical research Radiation safety Radioisotopes in medicine Radiotherapy Risk assessment Science, Technology, Communications

Radiopharmaceutical Review Improvement Act of 1996

Introduced: March 12, 1996 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 104th Congress ended
It never became law before the 104th Congress (1995–1996) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 18, 1996
Referred to the Subcommittee on Health and Environment.
Mar 12, 1996
Referred to the House Committee on Commerce.
Mar 12, 1996
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Radiopharmaceutical Review Improvement Act of 1996 - Amends the Federal Food, Drug, and Cosmetic Act (FDCA) to require that the safety and effectiveness of a radiopharmaceutical be determined: (1) weighing the probable health benefit against any probable risk of injury or illness; and (2) taking into account the absence or presence of pharmacological and toxicological activity of the radiopharmaceutical and the estimated absorbed dose. Allows the indications for which a radiopharmaceutical intended for diagnostic purposes is approved to refer to processes, processes common to or present in one or more disease states, or a diagnostic procedure used in the diagnosis of one or more diseases. Requires that, if a radiopharmaceutical is the primary mode of action in a combination of drugs, the persons charged with premarket review of radiopharmaceutical products have primary regulatory jurisdiction.

What's happening now March 18, 1996

Referred to the Subcommittee on Health and Environment.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Republican 1
R
Crapo, Mike
Idaho · Apr 15, 1996
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3065: Radiopharmaceutical Review Improvement Act of 1996. 104th Congress. Open America. https://openamerica.io/bill/104-HR-3065/
MLA
"H.R. 3065: Radiopharmaceutical Review Improvement Act of 1996." 104th Congress, 2026, Open America, https://openamerica.io/bill/104-HR-3065/.
Bluebook (legal)
H.R. 3065, 104th Cong. (2026), https://openamerica.io/bill/104-HR-3065/.
Markdown link
[H.R. 3065: Radiopharmaceutical Review Improvement Act of 1996](https://openamerica.io/bill/104-HR-3065/)
Report a problem